[Follow-up after the treatment of ovarian cancer - really without Ca 125?]

Ceska Gynekol. 2012 Dec;77(6):540-2.
[Article in Czech]

Abstract

Results of study MRC OV05 and EORTC/GCCG 55955 (Rustin et al.) have raised a considerable interest and controversy by questioning the early beginning of recurrent ovarian cancer treatment and the role of Ca 125 monitoring in the follow-up of ovarian cancer patients. Main pitfalls and limitations of this study are introduced in a survey. On their basis an author's opinion on the continuing role of Ca 125 monitoring is expressed with a possible benefit for the subgroup of patients with a solitary or operable relaps or those with new treatment possibilities or with inclusion to new clinical studies.

Publication types

  • English Abstract

MeSH terms

  • CA-125 Antigen / blood*
  • Female
  • Humans
  • Neoplasm Recurrence, Local / diagnosis*
  • Ovarian Neoplasms / diagnosis
  • Ovarian Neoplasms / therapy*

Substances

  • CA-125 Antigen